Abstract. Ovarian cancer is a disease that seriously threatens the health of women and results in a high mortality rate. The present study aimed to investigate the novel peptide OSTP (peptide for specifically targeting ovarian cancer) to provide new methods for the effective diagnosis and treatment of ovarian cancer. The nude mouse ovarian cancer model was established. With the use of phage peptide display in vivo, a novel 7-amino peptide for specific binding to ovarian cancer was screened from the FliTrx bacterial peptide display system. OSTP was compounded and labeled with fluorescent pigment 5-FAM. The specificity and affinity of OSTP were tested in the ovarian cancer cell line A2780 in vitro. The tumortargeting assays of OSTP were performed in vivo by injecting 5-FAM-OSTP into tumor-bearing mice. Clinical tissue specimens were tested by fluorescence staining following the addition of 5-FAM-OSTP. We found that the peptide specifically bound to ovarian cancer A2780 cells. Cell fluorescence staining showed that 5-FAM-OSTP obviously and specifically bound to ovarian cancer A2780 cells, particularly to the cell membrane. One hour after i.v. peptide injection, 5-FAM-OSTP specifically targeted the tumor tissues in the tumor-bearing mice. In the human pathological sections, 5-FAM-OSTP exhibited strong specific binding to ovarian cancer tissues. The cell membrane and cytoplasm of the cells exhibited a fluorescent signal. This signal was more evident on the cell membrane. The present results suggest that OSTP is a potential strategy for the development of new diagnostic strategies and drug-targeted therapies for ovarian cancer.
Introduction
Of all gynecological malignancies, ovarian carcinoma accounts for the highest number of cases of mortality in Europe (1), the United States (2) , and China (3). The current standard of care includes the combination of radical surgery and platinum-based chemotherapy. Among patients who have early-stage cancers, 90% can be cured using current therapies; however, this percentage declines substantially in patients with advanced disease (4) . Approximately 30% of patients with advanced-stage ovarian carcinoma survive 5 years after the initial diagnosis. Despite prolific drug development, the treatment of ovarian carcinoma is confronted with difficulties, such as metastatic bulky disease burden and stagnant mortality rates (5) . Thus, new methods for the early detection of ovarian carcinoma and effective treatment are important.
Targeted therapy is a new treatment strategy that aims to increase tumor selectivity while decreasing the toxic effects on healthy cells. Targeted therapies use specific molecules in tumor tissues as carriers of tumor-targeting drugs to improve anticancer drug delivery, drug-targeting specificity, and safety (6, 7) . Various antigens and receptors in carcinoma cells that differ from normal cells have been found. Numerous targets exist in ovarian carcinoma cells. The receptors include VEGFR, ER-α, ErbB, EGFR, and IGF-1R, among others (8) (9) (10) . The antigens include CA-125, TAG-72, PEM and Lewis-Y, among others (11, 12) . Various monoclonal antibodies directed toward specific antigens in patients with ovarian cancer have been reviewed and discussed (13) . However, the effect of clinical ovarian cancer treatment is not ideal (14) . The lack of an efficient targeting carrier system presents an obstacle to its efficacy.
Peptides have displayed traits that are suitable for diagnosis and targeted treatment. These traits include efficient tissue targeting and low toxicity (15) (16) (17) (18) (19) (20) . Phage display is a technique that fuses random peptides to the protein coat of a bacteriophage in a manner that makes them accessible to target ligands. The DNA that encodes the peptide sequence is protected within the virion (21) . This technology has facilitated significant developments that can be used in the long term. The identified 'homing' peptides are promising alternatives to the currently used biomolecules for targeting metastatic cells due to their rapid blood clearance, increased diffusion and tissue penetration, non-immunogenic nature, and ease of synthesis (19) .
The goal of this research was to identify a specific peptide sequence that binds to ovarian cancer cells for the further development of targeted treatment by screening a library of phage-displayed peptides in vivo. 4 cells/well) the day before use. Cells were washed, incubated in serum-free RPMi-1640 medium at 37˚C for 2 h, and then fixed in 4% paraformaldehyde in phosphatebuffered saline (PBS) for 15 min. Cells were washed thrice with Tris-buffered saline Tween-20 (TBST) and blocked with blocking buffer (TBST contained 3% BSA) at 37˚C for 1 h. The randomly selected amplified phage clones were each added into the cells at 10 12 pfu/well, and the plate was incubated at 37˚C for 1.5 h. Subsequently, unbound phage was removed by washing the plate thrice with TBST. To detect phage binging to the cells, the wells were incubated for 1 h with 100 µl/well of mouse anti-M13 antibody (dilution, 1:5,000 in the blocking buffer). After washing the plate thrice with TBST, 100 µl of HRP-conjugated sheep anti-mouse ig was added to each well (dilution, 1:5,000 in the blocking buffer). Subsequently, color development was induced by adding 100 µl/well of freshly prepared diaminobenzidine solution and then incubating the plate for 5 min at 37˚C. The plates were read on an automated ELISA plate reader at an absorbance of 490 nm. Triplicate determinations were performed at each data point. Selectivity was determined using the following formula: P/N (the positive phage OD/control phage OD) >2.1. The ELiSA-positive phage was expanded, and the single-stranded DNA clone sequence was detected. According to the base sequence, the short peptide amino acid sequence was obtained. The OSTP peptide and the control peptide NSTP, the amino acid of which was screened from another research, were detected. Then, 5-FAM was coupled at the nH 2 terminus. The peptides were synthesized by Shanghai Sangong Co., and then purified by high-performance liquid chromatography. The sequence and structure of the peptides were confirmed by mass spectrometry.
Cell fluorescence staining. Ovarian cancer A2780 cells and osteosarcoma MG63 cells were cultured at the logarithmic phase for use in the experiment. After pancreatic enzyme digestion and heavy suspension, the cells were adjusted to 2.5x10 5 /ml and then placed into 6 orifice plates for culture. in the experimental group, 2 µl (4.9 mg/ml) of 5-FAM-OSTP was added, whereas in the control group, 2 µl of 50% DMSO solvent agent was added. The cells were continuously cultured for 16 h while avoiding light. PBS was used to wash the plates. The cover glasses were removed when the cells were dry. The cells were then fixed with acetone for 15 min, washed, and exposed to antagonize fluorescence quenching agent to seal the pieces. The cells were examined for fluorescence by using laser scanning confocal microscopy (Olympus). Experiments were repeated thrice. The fluorescence distribution of the incubated A2780 cells was observed in different periods, and images were captured.
Tumor targeting. Tumor-bearing mice were used for targeting experiments. The tumors grew to a size of 1.0 to 2.0 cm 3 . OSTP (980 µg) was injected into the tail vein and allowed to circulate for 15 min. The control group was injected with nSTP (980 µg) and 20% DMSO (980 µg). The mice were perfused with PBS through the left ventricle to remove blood and unbound peptides. Tumors and control organs were excised, and frozen sections were prepared and examined for fluorescence using laser scanning confocal microscopy. Quantification of the imaging results was accomplished using Image-Pro Plus 6.0.
Affinity of OSTP to ovarian cancer tissues. Human ovarian cancer samples, human ovarian cystadenoma samples, other ovarian tumor samples, human normal ovarian samples, and human uterine samples were sectioned serially at 2 µm. After drying at 60˚C from 30 to 60 min, the slides were transferred to xylene I for 20 min, xylene II for 10 min, 100% ethanol for 5 min, 95% ethanol for 5 min, and then 85% ethanol for 5 min to be deparaffinized and rehydrated. The slides were then shaken and washed twice for 5 min with ddH 2 O and twice for 5 min with PBS. Antigen was retrieved by soaking the slides in pH 6.0 citric acid solution. The slides were blocked in BSA for 30 min at 37˚C in a chamber and then in 100 µl of 5-FAM-OSTP (2.0 mg/ml) for 1 h at 37˚C in a chamber kept away from light and sealed with a Na 2 CO 3 and glycerine solution. The slides were then observed, and images were captured under a fluorescence microscope. The same tissue slides were diagnosed through H&E staining.
Statistical analysis.
Values are expressed as mean ± SD. The significance of the difference from the respective controls for each experimental test condition was assayed using the Student's t-test for each paired experiment. A p-value of <0.05 or 0.01 was considered as indicative of a statistically significant result.
Results

Identification of a peptide that specifically binds to ovarian cancer cells.
Targeting peptides were selected in vivo by screening the FliTrx library with the ovarian carcinoma A2780 cells for three rounds. After each round of screening, the FliTrx concentration in the tumor tissues was significantly increased, whereas that in the control tissues was reduced. After the third round, 10 individual FliTrx clones were selected. To confirm the specific binding of the selected phages to A2780 cells, 10 independent phage clones were randomly selected for testing using cell-based ELISA. To calculate selectivity, the binding of each phage to the A2780 cells was compared with the original library locus coeruleus. The phage optical density ratio of >2.1 indicated that specific binding to the A2780 cells had occurred. The results showed that 8 phage clones apparently possessed the most specific binding capability (Fig. 1) . The peptide-encoding inserts of these clones were sequenced. One of the peptide sequences (PHLATLF) appeared 8 times in the selected clones.
OSTP specifically binds to ovarian cancer cells in vitro.
OSTP and nSTP were synthesized and labeled by 5-FAM from Shanghai Shenggong Co. (purity >95%). The solvent control group of the ovarian cancer A2780 cells did not produce fluorescence (the background is dark). MG63 cells also did not produce spontaneous fluorescence (Fig. 2) . However, the ovarian cancer A2780 cell cytoplasm and membrane produced bright yellow-green fluorescence after incubation with 5-FAM-OSTP. The results confirmed that 5-FAM-OSTP has specific combining capability with ovarian cancer A2780 cells, and the binding sites are mainly located on the cell membrane.
OSTP targets ovarian cancer tumors in vivo.
First, 5-FAM-OSTP (980 µg), 5-FAM-nSTP (980 µg), and 20% DMSO (980 µg) were injected into the tail vein of the mice and allowed to circulate for 15 min in each group. Second, tumors and control organs were excised and processed for frozen sectioning. The 5-FAM-OSTP specifically targeted tumors. in the liver and kidney very weak fluorescence was observed, whereas in other control organs, no visible fluorescence was observed (Fig. 3) . As shown in Fig. 4 , the results of the analysis of the average fluorescence intensity of organs using ImageJ software are shown. Compared with other tissues, the fluorescent intensity in tumor tissues was significantly higher (P<0.01). OSTP specifically binds to human ovarian cancer specimens. Yellow-green fluorescence was observed in the ovarian cancer tumor tissues. The fluorescence was brighter at the cell membrane and weaker in the cytoplasm. Very weak background fluorescence was observed in tumor stroma. 5-FAM-OSTP may specifically combine with ovarian cancer tissues that express various antigens. However, 5-FAM-OSTP did not combine with the endometria and uterine wall. 5-FAM-OSTP did not combine with other human ovarian tumors, ovarian cystadenoma and normal ovarian tissues (Fig. 5 and Table i ).
Discussion
Ovarian cancer remains a challenge for clinical treatment. The disease is incurable for the majority of patients due to relapse attributed to resistance to chemotherapeutic drugs (22) . The typically used chemotherapeutic drugs are carboplatin and paclitaxel. Novel drugs for targeted therapy are needed to reduce drug resistance and severe side effects, which are mainly caused by the non-cancer cell specificity of the agents and the insensitivity of cancer cells. Different avenues have been pursued to achieve this goal (23) .
Since 1990, the phage display has been successfully constructed, and peptide libraries have been widely applied for the in vivo and in vitro screening for research on target enzymes, carbohydrates, receptors, antibodies and nucleic acids (24) . A wide variety of tumor-specific binding peptides have been discovered through the phage display. These peptides include RGD-4C, NGR, CPRECES and GSL, which can target tumor vascular endothelium (25) (26) (27) . Pasqualini and colleagues (28, 29) were the first to screen peptides that combined specifically to the brain and kidney. They successfully screened another short peptide that included the RGD sequence, which can specifically bind to malignant melanoma and breast cancer integrin α (subunit v). By using phage display technology, a short peptide binding specifically to tumor vasculature was selected as a drug carrier of adriamycin for the targeted therapy of breast tumor-bearing mice in vivo with superior effects (30). Teesalu et al (31) found that tumorpenetrating peptides can bind to the NRP-1 protein, thereby significantly improving the drug penetration capability by increasing tumor accumulation. The use of targeted peptides has made significant progress in recent years. Yang et al (19) detected a novel tumor-homing peptide that specifically targets metastasis. The specific-binding peptide A54, which was screened from a phage display library, represents a promising approach for the development of novel targeted therapeutic strategies against hepatocellular carcinoma. The affinity peptide was discovered for targeted detection of dysplasia in Barrett's esophagus (18) . OA02 peptide-targeted polymeric micelle system was developed for effective paclitaxel delivery in an ovarian cancer xenograft mouse model (32) . Li et al (33) utilized a pro-apoptotic peptide conjugated to a Toll-like receptor and two mediated cell-penetrating peptides that target After the third round of screening, the peptide sequence (PHLTALF) appeared 8 times in ELiSA, thus illustrating that the short peptide has an effective concentration in vivo. A random peptide library contained the same specific fragment of phage. Thus, OSTP exhibited tissue-specific affinity. During the input of the first round of screening, the phage library was 2.0x10 11 pfu, thus ensuring that tens of thousands of short peptide sequences contained the short peptide in the ovarian cancer cell cytoplasm and membrane, in which some antigens that specifically bind to OSTP are present. High affinity to tumor tissues was observed after circling in vivo. The tumor tissues exhibited a strong fluorescence signal. Meanwhile, the control organs exhibited no visible fluorescence signal.
Identifying the receptor that binds to OSTP on the cell surface is important for better understanding of the molecular properties of OSTP. We are conducting further research to isolate the OSTP receptor. Affinity chromatography and timeof-flight delayed extraction MALDI mass spectrometry is being used for this purpose.
Moreover, OSTP was investigated using clinical tissue samples of ovarian cancer due to the differences between human ovarian cancer tissues from the cells cultured in vitro and simulative animal models. According to the immunofluorescence technique, meaningful results were obtained. immunofluorescence results demonstrated yellow-green fluorescence in the human ovarian cancer tissues. The fluorescence was mainly present on the cell membranes, whereas the stroma exhibited only weak background fluorescence. Ovarian cystadenoma, other ovarian tumors, and contrast uterine tissues did not show an obvious yellow-green fluorescent signal. The results demonstrated that OSTP has specificity for human ovarian cancer tissues.
Therefore, OSTP may be applied as a new ovarian cancer screening biomarker and a new targeting carrier that can be coupled with chemotherapy drugs. The peptide structure must be modified to improve stability in vivo and to increase water solubility so that when combined with a drug, the antitumor activity of the compound can be detected in ovarian cancer cells. Moreover, the anticancer therapeutic effect on ovarian cancer-bearing mice can be confirmed, and the pharmacokinetics of compound cycling in tumor-bearing mice can be studied. OSTP appears to be a useful tool for targeted treatment and diagnosis of ovarian cancer.
